| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3156 | Lu-002 | Novel β2-specific inhibitor, potently targeting both β2c and β2i, displaying moderate trypanocidal activity |
|
| DCC3157 | Lu-002c | Novel potent β2c-specific inhibitor, displaying moderate trypanocidal activity |
|
| DCC3158 | Lu-002i | Novel β2i-specific inhibitor, displaying moderate trypanocidal activity |
|
| DCC3159 | Lu-aa47070 | Potent and selective adenosine A2A receptor antagonist |
|
| DCC3160 | Lu-af11205 | Potent mGlu5 receptor positive allosteric modulator (PAM) |
|
| DCC3161 | Luf-5764 | A1 adenosine receptor antagonist |
|
| DCC3162 | Luf-6056 | Human adenosine A1 receptor antagonist |
|
| DCC3163 | Luf-6258 | Hybrid ortho/allosteric ligand of the adenosine A(1) receptor |
|
| DCC3164 | Lugdunin | Thiazolidine-containing cyclic peptide antibiotic, suppressing growth of species of disease-causing bacteria in that part of the human microbiome |
|
| DCC3165 | Luminespib Mesylate | Novel inhibitor of heat shock protein 90 (Hsp90) |
|
| DCC3166 | Luminolate (luminol Sodium Salt) | Immune modulator with SARS-CoV-2 antiviral activity via a multi-target mechanism including localized, self-limiting reactive oxygen species (ROS) scavenging activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammatio |
|
| DCC3167 | Lx7101 Hydrochloride | Novel Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma |
|
| DCC3168 | lxrβ-agonist-19 | Novel selective LXRβ agonist, reducing total brain Aβ |
|
| DCC3169 | Lxy6006 | Novel Manassantin A Derivative, Inhibiting Hypoxia-Inducible Factor 1 and Tumor Growth |
|
| DCC3170 | Lxy6090 | Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor |
|
| DCC3171 | Ly2019-005 | Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively |
|
| DCC3172 | Ly2019-006 | Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively |
|
| DCC3173 | Ly2048978 | Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders |
|
| DCC3174 | ly-2121260 | Novel glucokinase activator (GKA) |
|
| DCC3175 | ly-2140023 | Novel mGlu2/3 receptor agonist; Prodrug of LY-404039 |
|
| DCC3176 | Ly-231617 | Potent antioxidant, being cytoprotective in models of focal and global cerebral ischemia |
|
| DCC3177 | Ly2389575 | Selective negative allosteric modulator of mGlu3 |
|
| DCC3178 | Ly-278584 | Potent 5-HT3 serotonin receptor antagonist |
|
| DCC3179 | ly2886721 Hydrochloride | Orally active cell-permeable inhibitor of human |
|
| DCC3180 | Ly2934747 | Novel, potent, and systemically bioavailable mGlu2/3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo |
|
| DCC3181 | ly-294002 Hydrochloride | Selective cell permeable phosphatidylinositol 3-kinase (PI3K) inhibitor |
|
| DCC3182 | Ly2979165 Ammonium Salt | Novel highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3 |
|
| DCC3183 | Ly-333531 Mesylate | Potent and selective inhibitor of PKCβI and PKCβII |
|
| DCC3184 | Ly339434 | Potent GluR5 kainate receptor agonist |
|
| DCC3185 | Ly382884 | Selective GluR5 kainate receptor antagonist |
|
